Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Path Holdings

Full company profile

uuid0004ere

Namestring
Bio-Path Holdings
Legal namestring
Bio-Path Holdings, Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform. The platform combines a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes to deliver antisense DNA directly to cancer cells, a chemistry the company says avoids the dose-limiting toxicities of positively-charged lipid delivery systems. The company was founded in 2008 around technology licensed from The University of Texas MD Anderson Cancer Center and is headquartered in Pittsburgh, Pennsylvania, with prior external references placing it in Bellaire, Texas; it has been listed on NASDAQ Capital Market under ticker BPTH since 2014.

The pipeline consists of four core candidates: prexigebersen (BP1001), a liposomal Grb2 antisense in Phase 2 for acute myeloid leukemia (AML), including combination studies with venetoclax and decitabine; BP1001-A, a reformulation for advanced solid tumors (ovarian, endometrial, pancreatic) in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense in Phase 1 for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and venetoclax-resistant AML; and BP1003, a liposomal STAT3-targeting agent in IND-enabling studies for pancreatic adenocarcinoma. Prexigebersen has received Orphan Drug Designation from both the FDA (2015) and the EMA (2016). The company has 1-10 employees, has undergone three reverse stock splits since 2018, is reincorporating from Delaware to Wyoming in 2026, and installed Vikram Grover as Chairman and CEO in October 2025 with a turnaround mandate. Institutional ownership is reported at approximately 5.7%, well below the 32.4% industry average.

Commercially, Bio-Path is pre-revenue and generates no product or licensing income. Its business model is to advance candidates through clinical trials toward regulatory approval, with future revenue expected from direct commercialization or licensing of approved drugs. Operations are funded through periodic small dilutive equity raises, with roughly $9.2M raised across three 2024 private placements and registered direct offerings and an additional ~$2M raised in November 2022; a Regulation A offering is in preparation under the new leadership.

Short descriptiontext

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® neutral-charge liposomal delivery platform, with drug candidates in Phase 1 and Phase 2 trials for AML, lymphoma, and solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antisense DNA therapeutics, liposomal drug delivery, RNAi nanoparticle drugs, oncology therapeutics, targeted cancer therapy
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals / Oncology Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Bio-Path Holdings is a pre-revenue clinical-stage biotechnology company. The company does not currently generate commercial revenue. Future revenue will come from sales of approved drug products (prexigebersen, BP1001-A, BP1002, BP1003) if they receive regulatory approval, or from licensing/partnership deals with pharmaceutical companies for co-development or commercialization rights.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform, a neutral-charge liposome-based antisense DNA delivery system. The company is advancing a pipeline of four drug candidates—prexigebersen (BP1001), BP1001-A, BP1002, and BP1003—through Phase 1 and Phase 2 clinical trials for hematologic malignancies and solid tumors. The therapeutics are designed to inhibit specific cancer-driving proteins (Grb2, Bcl-2, STAT3) and are targeted primarily at elderly or fragile patients ineligible for high-dose chemotherapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2 combination trial: 3 of 6 evaluable patients achieved complete remission, 2 achieved stable disease
+3 more records
Product overview1 text field

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted cancer therapies leveraging its proprietary DNAbilize® platform technology for antisense DNA therapeutics delivery. The company's product portfolio consists of four main drug candidates in various clinical stages: Prexigebersen (BP1001), a liposomal Grb2 antisense for acute myeloid leukemia currently in Phase 2; BP1001-A, a modified formulation for solid tumors in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense for lymphoma and AML in Phase 1; and BP1003, a liposomal STAT3 targeting pancreatic cancer in IND-enabling studies. The DNAbilize® platform underlies all products, enabling delivery of antisense DNA through neutral-charge liposome technology that addresses traditional limitations of lipid-based delivery systems.

Product and service5 records
1Prexigebersen (BP1001)
CategoryOncology Therapeutic (Antisense DNA)
Description

Liposomal Grb2 antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2 (Grb2), essential in cancer progression via the RAS activation pathway. Currently in Phase 2 trials for acute myeloid leukemia (AML), including combination therapies with venetoclax and decitabine, targeted at elderly and fragile AML patients.

2BP1001-A
CategoryOncology Therapeutic (Solid Tumor Antisense)
Description

Modified formulation of prexigebersen incorporating the same Grb2 antisense drug substance with slightly modified nanoparticle properties designed to enhance delivery to solid tumors. Being evaluated in Phase 1 trials for advanced solid tumors including ovarian, endometrial, and pancreatic cancers, and in preclinical studies for obesity.

3BP1002 (Liposomal Bcl-2)
CategoryOncology Therapeutic (Antisense DNA)
Description

Neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Bcl-2, a protein involved in blocking programmed cell death. Being evaluated in Phase 1 trials for Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and AML patients who have relapsed from venetoclax-based treatment.

4BP1003 (Liposomal STAT3)
CategoryOncology Therapeutic (Solid Tumor RNAi)
Description

RNAi nanoparticle containing antisense DNA targeting STAT3, a protein associated with increased pancreatic adenocarcinoma severity and poorer survival. IND-enabling studies ongoing for pancreatic cancer with potential applications in non-small cell lung cancer and AML.

5DNAbilize® Platform Technology
CategoryDrug Delivery Platform Technology
Description

Patented neutral-charge liposome-based antisense DNA delivery system combining a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes, enabling systemic delivery of antisense therapeutics to cancer cells without dose-limiting toxicities associated with positively-charged lipid technologies.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2016-06-28
Description

Collaboration for systemic antisense immunotherapy treatment for brain cancer using Bio-Path's liposomal delivery technology. This partnership expands the application of the DNAbilize® platform beyond blood cancers into solid tumors of the central nervous system.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2016-03-23
Description

Research collaboration on autoimmune indication using Bio-Path's antisense delivery technology. This collaboration represents expansion of the platform technology into non-oncology therapeutic areas.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2016-03-08
Description

Pancreatic cancer research collaboration with leading oncology institution to advance BP1003 (Liposomal STAT3) for pancreatic adenocarcinoma treatment.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2009-09-22
Description

Foundational technology licensing agreement for the DNAbilize® platform technology from MD Anderson Cancer Center. The company was founded on this foundational technology and maintains a strong ongoing relationship with the Cancer Center for continued research collaboration and development of liposomal antisense therapeutics.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Ionis is the leading antisense oligonucleotide therapeutics company, with a mature pipeline including hematology and oncology programs. Directly comparable as both companies develop antisense-based nucleic acid therapeutics for cancer and rare diseases, and Ionis represents the gold-standard commercialization path Bio-Path aspires to.

TypeDirect peer
Description

Regulus develops microRNA-targeted therapeutics, with clinical programs in kidney disease and oncology. Comparable as a small-cap clinical-stage company developing nucleic acid-based therapeutics (microRNA antisense) with similar pre-revenue, partnership-dependent business model.

TypeDirect peer
Description

Sirnaomics develops RNAi-based therapeutics using its PNP (polymeric nanoparticle) delivery platform for oncology and fibrosis. Comparable as a clinical-stage RNAi therapeutics company using nanoparticle delivery technology to target cancer indications.

TypeDirect peer
Description

ProQR develops RNA-based therapeutics (Axiomer® RNA editing platform) for rare genetic diseases. Comparable as a small-cap clinical-stage RNA/nucleic acid therapeutics company targeting diseases with high unmet need, with similar pre-commercial risk profile.

TypeDirect peer
Description

Alnylam is the leading RNAi therapeutics company with approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra) and a lipid nanoparticle delivery platform. Comparable as a nucleic acid-based therapeutics developer using lipid-based delivery, though at vastly larger scale and commercial stage.

TypeEmerging player
Description

Cogent Biosciences is a clinical-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Comparable as a small-cap, clinical-stage, publicly traded oncology biotech with similar capital-raising dynamics and institutional ownership profile.

TypeDirect peer
Description

Arbutus develops RNAi therapeutics delivered via lipid nanoparticles (LNP) and oral delivery technology for HBV and oncology. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using lipid-based delivery — a closely adjacent technology paradigm to DNAbilize®.

TypeEmerging player
Description

Benitec uses DNA-directed RNA interference (ddRNAi) to silence disease-causing genes, with oncology and infectious disease programs. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using DNA-based mechanisms, with overlapping oncology indications.

TypeEmerging player
Description

Geron is a small-cap clinical-to-commercial stage oncology company developing telomerase inhibitor (imetelstat) for hematologic malignancies including AML and MDS. Comparable as a small-cap oncology company targeting AML with a single platform-derived asset, facing similar commercialization and capital risks.

TypeDirect peer
Description

Wave is a clinical-stage antisense oligonucleotide company developing stereopure nucleic acid therapeutics for rare and neurological diseases. Directly comparable as a small-cap clinical-stage antisense platform company with similar pre-revenue / clinical-development profile.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Path Holdings

Biopharmaceuticals / Oncology Therapeuticsbiopathholdings.com

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® neutral-charge liposomal delivery platform, with drug candidates in Phase 1 and Phase 2 trials for AML, lymphoma, and solid tumors.

What Bio-Path Holdings does

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform. The platform combines a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes to deliver antisense DNA directly to cancer cells, a chemistry the company says avoids the dose-limiting toxicities of positively-charged lipid delivery systems. The company was founded in 2008 around technology licensed from The University of Texas MD Anderson Cancer Center and is headquartered in Pittsburgh, Pennsylvania, with prior external references placing it in Bellaire, Texas; it has been listed on NASDAQ Capital Market under ticker BPTH since 2014.

The pipeline consists of four core candidates: prexigebersen (BP1001), a liposomal Grb2 antisense in Phase 2 for acute myeloid leukemia (AML), including combination studies with venetoclax and decitabine; BP1001-A, a reformulation for advanced solid tumors (ovarian, endometrial, pancreatic) in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense in Phase 1 for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and venetoclax-resistant AML; and BP1003, a liposomal STAT3-targeting agent in IND-enabling studies for pancreatic adenocarcinoma. Prexigebersen has received Orphan Drug Designation from both the FDA (2015) and the EMA (2016). The company has 1-10 employees, has undergone three reverse stock splits since 2018, is reincorporating from Delaware to Wyoming in 2026, and installed Vikram Grover as Chairman and CEO in October 2025 with a turnaround mandate. Institutional ownership is reported at approximately 5.7%, well below the 32.4% industry average.

Commercially, Bio-Path is pre-revenue and generates no product or licensing income. Its business model is to advance candidates through clinical trials toward regulatory approval, with future revenue expected from direct commercialization or licensing of approved drugs. Operations are funded through periodic small dilutive equity raises, with roughly $9.2M raised across three 2024 private placements and registered direct offerings and an additional ~$2M raised in November 2022; a Regulation A offering is in preparation under the new leadership.

Bio-Path Holdings firmographics

Firmographics
Name
Bio-Path Holdings
Legal name
Bio-Path Holdings, Inc.
Website
https://biopathholdings.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® neutral-charge liposomal delivery platform, with drug candidates in Phase 1 and Phase 2 trials for AML, lymphoma, and solid tumors.
Ownership category
akta.pro rank

Bio-Path Holdings industry classification

Industry
Product category
Biopharmaceuticals / Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antisense DNA therapeutics
  • Liposomal drug delivery
  • RNAi nanoparticle drugs
  • Oncology therapeutics
  • Targeted cancer therapy

Where Bio-Path Holdings is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Bio-Path Holdings business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Bio-Path Holdings is a pre-revenue clinical-stage biotechnology company. The company does not currently generate commercial revenue. Future revenue will come from sales of approved drug products (prexigebersen, BP1001-A, BP1002, BP1003) if they receive regulatory approval, or from licensing/partnership deals with pharmaceutical companies for co-development or commercialization rights.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Bio-Path Holdings product offering

Product offering

Core offering

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform, a neutral-charge liposome-based antisense DNA delivery system. The company is advancing a pipeline of four drug candidates—prexigebersen (BP1001), BP1001-A, BP1002, and BP1003—through Phase 1 and Phase 2 clinical trials for hematologic malignancies and solid tumors. The therapeutics are designed to inhibit specific cancer-driving proteins (Grb2, Bcl-2, STAT3) and are targeted primarily at elderly or fragile patients ineligible for high-dose chemotherapy.

Product overview

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted cancer therapies leveraging its proprietary DNAbilize® platform technology for antisense DNA therapeutics delivery. The company's product portfolio consists of four main drug candidates in various clinical stages: Prexigebersen (BP1001), a liposomal Grb2 antisense for acute myeloid leukemia currently in Phase 2; BP1001-A, a modified formulation for solid tumors in Phase 1 and preclinical obesity studies; BP1002, a liposomal Bcl-2 antisense for lymphoma and AML in Phase 1; and BP1003, a liposomal STAT3 targeting pancreatic cancer in IND-enabling studies. The DNAbilize® platform underlies all products, enabling delivery of antisense DNA through neutral-charge liposome technology that addresses traditional limitations of lipid-based delivery systems.

Differentiator

Problem solved

Functional benefit

Products and services

  • Prexigebersen (BP1001) Liposomal Grb2 antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2 (Grb2), essential in cancer progression via the RAS activation pathway. Currently in Phase 2 trials for acute myeloid leukemia (AML), including combination therapies with venetoclax and decitabine, targeted at elderly and fragile AML patients.
  • BP1001-A Modified formulation of prexigebersen incorporating the same Grb2 antisense drug substance with slightly modified nanoparticle properties designed to enhance delivery to solid tumors. Being evaluated in Phase 1 trials for advanced solid tumors including ovarian, endometrial, and pancreatic cancers, and in preclinical studies for obesity.
  • BP1002 (Liposomal Bcl-2) Neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of Bcl-2, a protein involved in blocking programmed cell death. Being evaluated in Phase 1 trials for Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and AML patients who have relapsed from venetoclax-based treatment.
  • BP1003 (Liposomal STAT3) RNAi nanoparticle containing antisense DNA targeting STAT3, a protein associated with increased pancreatic adenocarcinoma severity and poorer survival. IND-enabling studies ongoing for pancreatic cancer with potential applications in non-small cell lung cancer and AML.
  • DNAbilize® Platform Technology Patented neutral-charge liposome-based antisense DNA delivery system combining a neutral-charge P-ethoxy DNA backbone with neutral-charge liposomes, enabling systemic delivery of antisense therapeutics to cancer cells without dose-limiting toxicities associated with positively-charged lipid technologies.

Quantifiable outcome

  • Phase 2 combination trial: 3 of 6 evaluable patients achieved complete remission, 2 achieved stable disease
  • +3 more outcomes

Companies that use Bio-Path Holdings

Customer profile

Segments1 record

Ideal customer profiles3 records

Bio-Path Holdings technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bio-Path Holdings partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered secondary and core.

  • Thomas Jefferson UniversitysecondaryStrategic or Co-development Partner · 28 June 2016Collaboration for systemic antisense immunotherapy treatment for brain cancer using Bio-Path's liposomal delivery technology. This partnership expands the application of the DNAbilize® platform beyond blood cancers into solid tumors of the central nervous system.
  • The University of Texas Southwestern Medical CentersecondaryStrategic or Co-development Partner · 23 March 2016Research collaboration on autoimmune indication using Bio-Path's antisense delivery technology. This collaboration represents expansion of the platform technology into non-oncology therapeutic areas.
  • MD Anderson Cancer Center (Pancreatic Cancer Research)secondaryStrategic or Co-development Partner · 8 March 2016Pancreatic cancer research collaboration with leading oncology institution to advance BP1003 (Liposomal STAT3) for pancreatic adenocarcinoma treatment.
  • The University of Texas MD Anderson Cancer CentercoreTechnology or Integration · 22 September 2009Foundational technology licensing agreement for the DNAbilize® platform technology from MD Anderson Cancer Center. The company was founded on this foundational technology and maintains a strong ongoing relationship with the Cancer Center for continued research collaboration and development of liposomal antisense therapeutics.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Bio-Path Holdings competitors and assessment

Company assessment

Direct peers

  • Ionis Pharmaceuticals: Ionis is the leading antisense oligonucleotide therapeutics company, with a mature pipeline including hematology and oncology programs. Directly comparable as both companies develop antisense-based nucleic acid therapeutics for cancer and rare diseases, and Ionis represents the gold-standard commercialization path Bio-Path aspires to.
  • Regulus Therapeutics: Regulus develops microRNA-targeted therapeutics, with clinical programs in kidney disease and oncology. Comparable as a small-cap clinical-stage company developing nucleic acid-based therapeutics (microRNA antisense) with similar pre-revenue, partnership-dependent business model.
  • Sirnaomics: Sirnaomics develops RNAi-based therapeutics using its PNP (polymeric nanoparticle) delivery platform for oncology and fibrosis. Comparable as a clinical-stage RNAi therapeutics company using nanoparticle delivery technology to target cancer indications.
  • ProQR Therapeutics: ProQR develops RNA-based therapeutics (Axiomer® RNA editing platform) for rare genetic diseases. Comparable as a small-cap clinical-stage RNA/nucleic acid therapeutics company targeting diseases with high unmet need, with similar pre-commercial risk profile.
  • Alnylam Pharmaceuticals: Alnylam is the leading RNAi therapeutics company with approved drugs (Onpattro, Givlaari, Oxlumo, Amvuttra) and a lipid nanoparticle delivery platform. Comparable as a nucleic acid-based therapeutics developer using lipid-based delivery, though at vastly larger scale and commercial stage.
  • Arbutus Biopharma: Arbutus develops RNAi therapeutics delivered via lipid nanoparticles (LNP) and oral delivery technology for HBV and oncology. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using lipid-based delivery — a closely adjacent technology paradigm to DNAbilize®.
  • Wave Life Sciences: Wave is a clinical-stage antisense oligonucleotide company developing stereopure nucleic acid therapeutics for rare and neurological diseases. Directly comparable as a small-cap clinical-stage antisense platform company with similar pre-revenue / clinical-development profile.

Emerging players

  • Cogent Biosciences: Cogent Biosciences is a clinical-stage precision oncology company developing kinase inhibitors for genomically defined cancers. Comparable as a small-cap, clinical-stage, publicly traded oncology biotech with similar capital-raising dynamics and institutional ownership profile.
  • Benitec Biopharma: Benitec uses DNA-directed RNA interference (ddRNAi) to silence disease-causing genes, with oncology and infectious disease programs. Comparable as a small-cap clinical-stage nucleic acid therapeutics company using DNA-based mechanisms, with overlapping oncology indications.
  • Geron Corporation: Geron is a small-cap clinical-to-commercial stage oncology company developing telomerase inhibitor (imetelstat) for hematologic malignancies including AML and MDS. Comparable as a small-cap oncology company targeting AML with a single platform-derived asset, facing similar commercialization and capital risks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Bio-Path Holdings social profiles

Digital presence

Bio-Path Holdings compliance and trust

Trust signal

Compliance2 records

Bio-Path Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Path Holdings leadership team

Management profile

Number of profiles

Profiles7 records

Bio-Path Holdings funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Path Holdings M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Path Holdings

What does Bio-Path Holdings do?

Bio-Path Holdings is a clinical-stage biotechnology company developing targeted nucleic acid cancer therapeutics using its proprietary DNAbilize® platform, a neutral-charge liposome-based antisense DNA delivery system. The company is advancing a pipeline of four drug candidates—prexigebersen (BP1001), BP1001-A, BP1002, and BP1003—through Phase 1 and Phase 2 clinical trials for hematologic malignancies and solid tumors. The therapeutics are designed to inhibit specific cancer-driving proteins (Grb2, Bcl-2, STAT3) and are targeted primarily at elderly or fragile patients ineligible for high-dose chemotherapy.

Is Bio-Path Holdings a public or private company?

Bio-Path Holdings is a public company. It is classified as public and is currently operating.

When was Bio-Path Holdings founded?

Bio-Path Holdings was founded in 2008. It employs 1 to 10 people.

Where is Bio-Path Holdings based?

Bio-Path Holdings is headquartered in Houston, United States, in the North America region.

How does Bio-Path Holdings make money?

One revenue line is on record: drug Development and Commercialization.

Who are Bio-Path Holdings's main competitors?

Direct peers on record are Ionis Pharmaceuticals, Regulus Therapeutics, Sirnaomics, ProQR Therapeutics, Alnylam Pharmaceuticals, Arbutus Biopharma and Wave Life Sciences. Emerging players are Cogent Biosciences, Benitec Biopharma and Geron Corporation.

Does Bio-Path Holdings have an API?

No public API is recorded for Bio-Path Holdings.

What industry is Bio-Path Holdings in?

Bio-Path Holdings's product category is Biopharmaceuticals / Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBitPath Holdings To Launch Tokenize Campaign for Over-The-Counter Market, Launches SPV for Qualified IssuersBitPath Holdings announced plans to tokenize equity and debt of OTCM issuers via a new SPV called Tokenize, which will issue blockchain-backed tokens. The company will begin trading on the Expert Market on September 8, 2026, and set a record date of September 25, 2026 for a potential token dividend.YellowYellow.comaltFINS j.s.a. announced a partnership with BitPath Holdings, Inc. (OTC: BPTH) to launch a Gen 2 Digital Asset Treasury strategy, providing analytics, market intelligence and active portfolio management. BitPath issued 2,561,822 restricted shares, 4.9% of outstanding, and may invest up to two million euros for up to 22% ownership. altFINS will take a 1.25% management fee plus performance bonuses.EIN PresswireBitPath Holdings Launches Gen 2 Digital Asset Treasury Strategy with altFINS Using AI Analytics and Active ManagementBitPath Holdings launched its Gen 2 Digital Asset Treasury strategy with altFINS, using AI analytics and active management. The partnership includes 2.56 million restricted shares (4.9% stake) and altFINS' CEO on the advisory board. The strategy targets blockchain-AI projects and expects to be funded by a Reg A financing.MarketScreenerBio-Path Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026Bio-Path Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2026. The company is engaged in developing DNAbilize technology and RNAi nanoparticle drugs, with its lead candidate prexigebersen currently in Phase II studies for blood cancers. The article provides a company profile and financial estimates but lacks specific numerical earnings data or strategic developments.EIN PresswireBIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE SPLITBio-Path Holdings announced a repositioning strategy, adding four strategic advisors and canceling a previously approved 1-for-30 reverse stock split. The company has over ten million shares outstanding and plans to restart Phase 2 trials for acute myeloid leukemia. It also engaged Farrington Capital and GT Securities for operational and financial support.openPR.comAntisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path HoldinDelveInsight Business Research LLP has published a pipeline insight report indicating that over 70 pharmaceutical companies are advancing more than 90 antisense oligonucleotide therapies for genetic and rare diseases. Key players including Novartis, Wave Life Sciences, and Bio-Path Holdings are leading with candidates in Phase III and Phase I clinical stages for conditions such as hyperlipoproteinaemia, Duchenne muscular dystrophy, and lymphoma. The FDA released new guidance in February 2026 to accelerate individualized ASO therapies, while Japan granted orphan drug designation to an antisense candidate for myotonic dystrophy, reflecting growing global regulatory support for RNA-targeted treatments.Defense WorldHead to Head Contrast: Bio-Path (BPTH) & Its CompetitorsThis article presents a comparative financial analysis between Bio-Path Holdings, Inc. (BPTH) and its competitors in the pharmaceutical preparations industry, examining metrics including beta/volatility, profitability, ownership structure, and valuation.Defense WorldBio-Path (BPTH) versus The Competition Critical SurveyThis article presents a comparative analysis between Bio-Path Holdings, Inc. and its pharmaceutical preparations industry peers across nine financial metrics, with competitors outperforming Bio-Path on six of those factors. Key findings include Bio-Path's negative beta of -0.33 indicating lower volatility than the S&P 500, significantly lower institutional ownership at 5.7% compared to the industry average of 32.4%, and superior profitability metrics despite lower revenue. Bio-Path is trading at a higher price-to-earnings ratio than peers, suggesting it is currently valued at a premium relative to comparable companies in its sector.Investing.comBio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.comBio-Path Holdings issued 51 Series S Preferred shares and 2 million warrants to Steel Giants Advisors LLC as payment for consulting services, while filing to reincorporate from Delaware to Wyoming with expected approval in March. The company is restructuring, has engaged Farrington Capital Group to review operations, and is evaluating the potential restart of certain drug trials for acute myeloid leukemia and solid tumors. The board also canceled a previously approved 1-for-30 reverse stock split, citing limited outstanding shares.BenzingaBio-Path Holdings Shares Were On The Rise: What's Going On? - BIO-PATH HOLDINGS INC by Bio-Path Holdings,Bio-Path Holdings announced encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes, showing the compound enhances insulin sensitivity by downregulating growth factor receptor-bound protein 2 (GRB2). Following these findings, the company initiated animal studies to validate efficacy, with plans for a first-in-human Phase 1 clinical trial in 2025 pending successful outcomes. The announcement drove Bio-Path Holdings shares up 104.8% to $1.37.